In addition, when we knocked out IFNGR1 in EMT6 tumor cells (Supplementary Fig. 7H), cells retained their ability to form tumors in vivo (Supplementary Fig. 7I), but the anti-tumor efficacy of the anti-PD-L1/TGFβ combination decreased (Fig. 6h). The gene discussed is IFNGR1; the disease is neoplasm.